| Revenue growth | 31.5% like-for-like growth in FY26, outperforming market by 1.6x. |
|---|---|
| Margins | EBITDA margins expanded 67bps YoY to 4% via better product mix. |
| Demand visibility | Strong visibility across pharma and diagnostics; expanding into new medical segments. |
| Management confidence | Balanced and confident, emphasizing transition from M&A to organic execution. |
Growth
Growth was driven by 31.5% organic like-for-like revenue increase and aggressive MedTech expansion contributing ₹1,000cr annually.
Outlook
FY27 guidance: 23% consolidated revenue growth and 5% EBITDA margins without new acquisitions.
Risks
High minority interest impacts PAT; working capital remains sensitive to MedTech's longer payable cycles.
Earnings Call filed with NSE, NSE: ENTERO. Summary written with AI assistance from the document.
Entero Healthcare Solutions Ltd: key numbers
- Share price
- ₹1,821.80
- Market cap
- ₹7,929 Cr
- Revenue (annual)
- ₹6,591 Cr
- Net profit (annual)
- ₹115.0 Cr
- P/E (TTM)
- 63.2×Sector 57.8×
- Promoter holding
- 52.40%-0.02% QoQ
- FII holding
- 4.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Entero Healthcare Solutions Ltd
All →Entero Healthcare Solutions Capital Structure Change
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions Legal & Regulatory
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
- Value
- ₹0.13 Cr
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern for the period ended March 31, 2026, as per regulatory requirements.
Entero Healthcare Solutions Earnings Call Transcript: Key Takeaways
Entero delivered a strong Q1 FY27 with 38.2% revenue growth and hit its full-year EBITDA margin target of 5% in the first quarter itself, signaling rapid structural margin expansion.
- Call
- Guides 23% growth
Entero Healthcare Solutions Investor Presentation: Key Takeaways
Q1FY27 revenue grew 38.2% YoY to ₹1,940.5 Cr with significant margin expansion. Strategy focuses on MedTech scaling and consolidating India's fragmented pharmaceutical distribution market.
Entero Healthcare Solutions Q1 FY27 Results: Net Profit ₹52.1 Cr, Up 72.5% YoY
Entero Healthcare Solutions Ltd reported revenue from operations of ₹1,940 Cr (+38.2% YoY) and net profit of ₹52.1 Cr (+72.5% YoY) for Q1 FY27.
- Key figure
- Net profit ₹52.1 Cr · +72.5% YoY